Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

706 articles

Showing 49–59 of 59 articles · Keyword: Nanocarriers Clear keyword

2014ReviewNon-viral Gene Delivery

49. Nanocarrier-based immunotherapy in cancer management and research

Singh Ms, Bhaskar S.

Cancer immunotherapy can induce specific antitumor immunity, control metastases, and provide immunological memory, but faces barriers including immunosuppressive tumour microenvironments and poor delivery of immunomodulators. Nanocarriers offer a versatile way to deliver antigens, adjuvants, cytokines, antibodies…

Read the article
European Journal of Pharmaceutics and Biopharmaceutics.2014ReviewNon-viral Gene Delivery

50. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – A systematic review of in vitro data

Slavomíra Doktorovová, Eliana B. Souto, Amélia Maria Silva

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were developed as alternative colloidal carriers with better stability and tolerability than polymeric nanoparticles. However, in vitro toxicity data were scattered across many cell lines, assays, exposure times, concentrations, and formulations…

Read the article
Drug Discovery Today.2013ReviewDrug Delivery

51. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers

Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, Liu J, Gan Y

Topical ocular drug delivery is limited by tear turnover, corneal and conjunctival barriers, efflux transporters, and poor water solubility of many drug candidates. Lipid-based nanocarriers may improve ocular bioavailability, prolong preocular residence, enhance corneal penetration, and provide controlled release…

Read the article
Journal of Controlled Release2013ReviewNon-viral Gene Delivery

52. Chitosan-based siRNA delivery systems

Ragelle, H.; Vandermeulen, G.; Préat, V

Chitosan is attractive for siRNA delivery because it is cationic, biocompatible, biodegradable, mucoadhesive, and permeation-enhancing. However, native chitosan suffers from low solubility at physiological pH, poor buffering capacity, instability in biological fluids, and insufficient endosomal escape, limiting…

Read the article
Biomedical Materials* (*Biomed. Mater.*)2012ReviewNon-viral Gene Delivery

53. Engineered Nonviral Nanocarriers for Intracellular Gene Delivery Applications

Not Fully Listed In The Supplied File; Corresponding Authors Are Isaac Ojea ([email protected]) And Victor Puntes ([email protected])

Viral vectors give high gene-transfer efficiency but carry risks of immunogenicity, oncogenic transformation, limited cargo capacity, and manufacturing difficulty. Nonviral nanocarriers are safer and cheaper alternatives, but they still suffer from low transfection efficiency because of extracellular and…

Read the article
Current Opinion in Lipidology2012ReviewNon-viral Gene Delivery

54. Lipid-based carriers of microRNAs and intercellular communication

Vickers Kc, Remaley At

Extracellular miRNAs are unusually stable in plasma and their circulating levels change with disease, making them promising biomarkers. They are associated with lipid-based carriers—exosomes, microvesicles, apoptotic bodies, and lipoproteins—as well as lipid-free proteins. Whether these carriers mediate functional…

Read the article
Nature Reviews Drug Discovery2010ReviewDrug Delivery

56. Strategies in the Design of Nanoparticles for Therapeutic Applications

Robby A. Petros And Joseph M. Desimone

Engineered nanoparticles have shown promise for targeted drug delivery, but first-generation systems (liposomes and polymer–drug conjugates) have not overcome all biological barriers required for effective therapy. Key barriers include opsonisation and RES clearance, inefficient cargo encapsulation and triggered…

Read the article
Journal of Internal Medicine2010ReviewNon-viral Gene Delivery

57. Lipid-based nanotherapeutics for siRNA delivery

Schroeder A, Levins Cg, Cortez C, Langer R, Anderson Dg

RNAi has strong therapeutic potential, but clinical translation of siRNA is limited by delivery. siRNA is large, negatively charged, susceptible to nuclease degradation, poorly taken up by cells, and must reach the cytoplasm to engage RISC. Safe and effective lipid-based delivery systems are needed to protect siRNA…

Read the article
Trends in Immunology2002ReviewNon-viral Gene Delivery

58. Caveolae and Caveolin in Immune Cells: Distribution and Functions

James Harris, Dirk Werling, Jayne C. Hope, Geraldine Taylor, Chris J. Howard

Caveolae and caveolin are cholesterol-rich membrane microdomains involved in endocytosis, cholesterol regulation, and signal transduction, but their presence and function in immune cells have been contentious. This review addresses the need to clarify the distribution and roles of caveolae/caveolin in mammalian…

Read the article
1989ReviewNon-viral Gene Delivery

59. Cationic liposome-mediated transfection

Felgner Pl, Ringold Gm

Existing polynucleotide delivery methods—calcium phosphate, DEAE-dextran, electroporation, retroviral vectors—had limitations in convenience, reproducibility, efficiency, and applicability across cell types. A simple, broadly effective cationic liposome reagent was needed for DNA and RNA transfection of mammalian…

Read the article
Articles — page 3 | Brilliant Blue Biosciences